Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Total Inventories : $24.2 Mil (As of Sep. 2017)

View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Total Inventories?

Sucampo Pharmaceuticals's total inventories for the quarter that ended in Sep. 2017 was $24.2 Mil. Sucampo Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2017 to the quarter that ended in Sep. 2017 was $23.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sucampo Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2017 was $-5.07.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sucampo Pharmaceuticals's Days Inventory for the three months ended in Sep. 2017 was 123.70.

Inventory Turnover measures how fast the company turns over its inventory within a year. Sucampo Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2017 was 0.74.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sucampo Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2017 was 0.39.

Sucampo Pharmaceuticals Total Inventories Historical Data

The historical data trend for Sucampo Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Total Inventories Chart

Sucampo Pharmaceuticals Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Inventories

Get a 7-Day Free Trial

0.21

33.12

23.47

Sucampo Pharmaceuticals Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Total Inventories	Get a 7-Day Free Trial															24.20	23.47	22.98	23.10	24.18

Sucampo Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Sucampo Pharmaceuticals (NAS:SCMP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Sucampo Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2017 is

	Net-Net Working Capital Per Share (Q: Sep. 2017 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(75.041	+	0.75 * 33.098	+	0.5 * 24.176	-	348.51
-	0	-	0)	/	46.6369
=	-5.07

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sucampo Pharmaceuticals's Days Inventory for the three months ended in Sep. 2017 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2017 )	/	Cost of Goods Sold (Q: Sep. 2017 )	*	Days in Period
	=	23.637	/	17.436	*	365 / 4
	=	123.70

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sucampo Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2017 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2017 )	/	Average Total Inventories (Q: Sep. 2017 )
	=	17.436	/	23.637
	=	0.74

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sucampo Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2017 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2017 )	/	Revenue (Q: Sep. 2017 )
	=	23.637	/	61.266
	=	0.39

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Sucampo Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Total Inventories

Traded in Other Exchanges

N/A

Address

Website

http://www.sucampo.com

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Executives

Peter Greenleaf	officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell	director
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan	officer: Sr. Vice Pres., BD & Licensing	C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener	officer: Chief Science Officer	40 GUEST STREET, BOSTON MA 02135
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh	officer: CFO	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp	other: Former Officer	4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin	director	18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris	officer: Chief Acctg. Officer, Treas.	C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814